Literature DB >> 10213477

Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor.

X M Li1, J Chlan-Fourney, A V Juorio, V L Bennett, S Shrikhande, D L Keegan, J Qi, A A Boulton.   

Abstract

Neuroanatomical studies of schizophrenia suggest that progressive neuropathological changes (such as neuronal atrophy and/or cell death) occur over the lifetime course of the disease. Early intervention with atypical neuroleptics has been shown to prevent progression of at least some symptoms, although the mechanisms by which neuroleptics may do this remain unknown. In this study, PC12 cells were used to determine the effects of the new atypical antipsychotic olanzapine on the gene expression of superoxide dismutase (SOD1) and the low affinity nerve growth factor receptor (p75). The results show that olanzapine increases SOD1 at concentrations of 10 and 100 microM after 48 hr of incubation in PC12 cultures. The treatment decreases p75 gene expression at concentrations 100 microM after 48 hr of incubation. Since both the upregulation of SOD1 mRNA and the antisense blockade of p75 mRNA have been associated with reduced cell death, our results suggest that olanzapine has neuroprotective potential and thus may be useful in preventing further neurodegeneration accompanying schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213477     DOI: 10.1002/(SICI)1097-4547(19990401)56:1<72::AID-JNR9>3.0.CO;2-0

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

Review 1.  Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models.

Authors:  Jue He; Jiming Kong; Qing-Rong Tan; Xin-Min Li
Journal:  Cell Adh Migr       Date:  2009-01-13       Impact factor: 3.405

Review 2.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 3.  Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Authors:  Christoph U Correll; Marta Hauser; Andrea M Auther; Barbara A Cornblatt
Journal:  J Child Psychol Psychiatry       Date:  2010-02-26       Impact factor: 8.982

4.  Effects of aripiprazole and clozapine on the treatment of glycolytic carbon in PC12 cells.

Authors:  Akira Ota; Akira Nakashima; Yoko S Kaneko; Keiji Mori; Hiroshi Nagasaki; Takeshi Takayanagi; Mitsuyasu Itoh; Kazunao Kondo; Toshiharu Nagatsu; Miyuki Ota
Journal:  J Neural Transm (Vienna)       Date:  2012-03-04       Impact factor: 3.575

Review 5.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Antidepressants upregulate messenger RNA levels of the neuroprotective enzyme superoxide dismutase (SOD1).

Authors:  X M Li; J Chlan-Fourney; A V Juorio; V L Bennett; S Shrikhande; R C Bowen
Journal:  J Psychiatry Neurosci       Date:  2000-01       Impact factor: 6.186

7.  Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.

Authors:  Stéphane Bastianetto; Marc Danik; Françoise Mennicken; Sylvain Williams; Rémi Quirion
Journal:  BMC Neurosci       Date:  2006-03-30       Impact factor: 3.288

Review 8.  The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment.

Authors:  Anna Giménez-Palomo; Seetal Dodd; Gerard Anmella; Andre F Carvalho; Giselli Scaini; Joao Quevedo; Isabella Pacchiarotti; Eduard Vieta; Michael Berk
Journal:  Front Psychiatry       Date:  2021-07-06       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.